First in a pipeline of new treatments

Rheumatoid arthritis affects one in every hundred people worldwide. A painful, chronic autoimmune disease, if untreated it can cause severe disability. Up to thirty per cent of patients do not respond to current medications, and there is no cure.

MBS2320 is a first-in-class metabolic reprogramming agent which has demonstrated proof-of-concept in patients with rheumatoid arthritis.

MBS2320 acts by selectively and subtly reprogramming mitochondrial metabolism. In Phase 2 studies this reduced inflammation, protected from disease progression and yielded clinical benefits to patients.

The results from this study show, for the first time, the potential of metabolic reprogramming to treat autoimmune disease in humans.